Le Lézard
Classified in: Health
Subjects: MAV, SCZ, FVT

/R E P E A T -- Media Invitation - Ludovick Bourgeois and the Canadian Cancer Society want to dethrone colon cancer/


Colon cancer, the second leading cause of death from cancer, is often silent.
But a simple at-home test can detect the disease early.

MONTREAL, March 8, 2019 /CNW Telbec/ -

 

WHAT:

Canadian Cancer Society (CCS) press event to educate Quebecers between the ages of 50 and 74 ? one-third of the population ? about the fact that a test that takes less than two minutes to take at home helps detect the disease at an early stage, BEFORE the signs and symptoms appear.



WHEN:

Saturday, March 9, 2019




From 10:30 am to 12:00 pm




Interviews with:


  • Singer Ludovick Bourgeois, spokesman for the CCS's "Let's dethrone colon cancer" campaign, son of Patrick Bourgeois, who sadly died from colon cancer in the fall of 2017
  • Dr Josée Parent, President of the Association des gastro-entérologues du Québec 
  • Yves Dubé, a man who was diagnosed with colon cancer at the age of 50, after taking an at-home screening test 
  • A Canadian Cancer Society representative       

A press briefing will take place at around 11 am. Interviews can be done before or after the event.



WHERE:

Canadian Cancer Society


5151 de l'Assomption Blvd., Montreal

 

  • One in two cases of colorectal cancer is diagnosed after it has spread to other parts of the body. However, when colon cancer is detected and treated at an early stage, the odds of successfully being treated increase and the five-year survival rate jumps to over 90%. At an advanced stage, the survival rate is only 13%.
  • Each year, around 6,800 Quebecers are diagnosed with colon cancer and 2,550 people die from the disease.
  • Nearly 95% of colon cancer cases occur after the age of 50.
  • Info: detrononslecancer.ca

 

SOURCE Canadian Cancer Society, Quebec Division


These press releases may also interest you

at 04:00
Today Benchling announced that Zealand Pharma A/S, ("Zealand") a biotechnology company focused on the discovery and development of peptide-based medicines, has selected the Benchling R&D Cloud as its central source of truth for scientific data,...

at 03:38
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today an update from a Type C meeting with the FDA, regarding the company's plans for a global...

at 03:35
The Japan Prize Foundation (President: Hiroshi Komiyama) held an award ceremony on Tuesday, April 16 at the Imperial Hotel Tokyo in Tokyo's Chiyoda Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the...

at 03:30
AMSilk GmbH ("AMSilk"), a global leader in advanced materials made from spider silk-based proteins, today announces the appointments of Ralph Fraundorfer and Ctibor Kohutovic to its Management Board starting immediately. Ralph Fraundorfer has been...

at 02:54
HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature...

at 02:50
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany?Universitätsklinikum Tübingen...



News published on and distributed by: